A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

Chidamide has demonstrated significant clinical benefits for patients with relapsed/refractory (R/R) PTCL in previous studies. This multi-center observational study was aimed to evaluate the objective response rate (ORR), overall survival (OS), and safety of chidamide. From February 2015 to December...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Weiping, Zhao, Donglu, Liu, Ting, Niu, Ting, Song, Yongping, Xu, Wei, Jin, Jie, Cai, Qingqing, Huang, Huiqiang, Li, Zhiming, Hou, Ming, Zhang, Huilai, Zhou, Jianfeng, Hu, Jianda, Shen, Jianzhen, Shi, Yuankai, Yang, Yu, Zhang, Liling, Zhao, Weili, Ding, Kaiyang, Qiu, Lugui, Tan, Huo, Zhang, Zhihui, Liu, Lihong, Wang, Jinghua, Xu, Bing, Zhou, Hui, Gao, Guangxun, Xue, Hongwei, Bai, Ou, Feng, Ru, Huang, Xiaobing, Yang, Haiyan, Yan, Xiaojing, Zeng, Qingshu, Liu, Peng, Li, Wenyu, Mao, Min, Su, Hang, Wang, Xin, Xu, Jingyan, Zhou, Daobin, Zhang, Hongyu, Ma, Jun, Shen, Zhixiang, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602952/
https://www.ncbi.nlm.nih.gov/pubmed/34804937
http://dx.doi.org/10.3389/fonc.2021.750323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602952/
https://www.ncbi.nlm.nih.gov/pubmed/34804937
http://dx.doi.org/10.3389/fonc.2021.750323

Ejemplares similares